Clinical Trial Update: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating a radiolabeled monoclonal antibody with rituximab, with/without filgrastim and interleukin-11, in relapsed or refractory non-Hodgki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Filgrastim (filgrastim)
• Interleukin-11 (interleukin-11)
• Radiolabeled monoclonal antibody (unspecified in title)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-12-17